Maini R - Search Results

1

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Maini R, et al. Lancet. 1999 Dec 4;354(9194):1932-9. doi: 10.1016/s0140-6736(99)05246-0. Lancet. 1999. PMID: 10622295 Clinical Trial.

2

Infliximab in active early rheumatoid arthritis.

Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, St Clair EW, Weisman M, Smolen J, Lipsky PE, Maini RN. Breedveld FC, et al. Among authors: maini rn. Ann Rheum Dis. 2004 Feb;63(2):149-55. doi: 10.1136/ard.2003.013961. Ann Rheum Dis. 2004. PMID: 14722203 Free PMC article. Clinical Trial.

3

Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions.

Taylor PC, Williams RO, Maini RN. Taylor PC, et al. Among authors: maini rn. Curr Dir Autoimmun. 2000;2:83-102. doi: 10.1159/000060499. Curr Dir Autoimmun. 2000. PMID: 11791460 Review. No abstract available.

4

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).

Bondeson J, Maini RN. Bondeson J, et al. Among authors: maini rn. Int J Clin Pract. 2001 Apr;55(3):211-6. Int J Clin Pract. 2001. PMID: 11351775 Review.

5

Workshop summary: health outcomes and health economic issues surrounding the use of biological therapies in patients with rheumatoid arthritis.

Maini RN, Wolfe F. Maini RN, et al. Rheumatology (Oxford). 1999 Nov;38 Suppl 2:48-9. Rheumatology (Oxford). 1999. PMID: 10646493 No abstract available.

6

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.

Maini RN, Taylor PC, Paleolog E, Charles P, Ballara S, Brennan FM, Feldmann M. Maini RN, et al. Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I56-60. doi: 10.1136/ard.58.2008.i56. Ann Rheum Dis. 1999. PMID: 10577974 Free PMC article. Review. No abstract available.

7

The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?

Feldmann M, Bondeson J, Brennan FM, Foxwell BM, Maini RN. Feldmann M, et al. Among authors: maini rn. Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I27-31. doi: 10.1136/ard.58.2008.i27. Ann Rheum Dis. 1999. PMID: 10577970 Free PMC article. Review.

8

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN. Charles P, et al. Among authors: maini rn. J Immunol. 1999 Aug 1;163(3):1521-8. J Immunol. 1999. PMID: 10415055 Clinical Trial.

9

Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.

Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN. Feldman M, et al. Among authors: maini rn. Transplant Proc. 1998 Dec;30(8):4126-7. doi: 10.1016/s0041-1345(98)01365-7. Transplant Proc. 1998. PMID: 9865320 Review. No abstract available.

10

Rheumatoid arthritis. A paradigm of inflammatory disease of the musculoskeletal system.

Maini RN. Maini RN. Acta Orthop Scand Suppl. 1998 Jun;281:6-13. Acta Orthop Scand Suppl. 1998. PMID: 9771534 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results